Dexcom, Inc. CEO Transition and Compensation Update

Dexcom, Inc. has announced a significant leadership change. Effective January 1, 2026, Jacob S. Leach will assume the role of Chief Executive Officer, succeeding Kevin R. Sayer, who is on medical leave and expected to return in March 2026. Mark Foletta will continue as interim Chairman of the Board until Mr. Sayer’s return. In connection with his promotion, Mr. Leach has entered into an offer letter detailing his new compensation package. This includes an annual base salary of $1,150,000, an annual target bonus opportunity of 150% of his base salary, and grants of restricted stock units (RSUs) and performance stock units (PSUs), each with a target fair value of $7,500,000. The RSUs will vest annually over three years, while the PSUs are subject to performance conditions. Mr. Leach will also continue to be eligible for the company’s severance and change in control plan and other employee benefit plans. The company has also filed an 8-K form detailing these changes and compensation arrangements, including the offer letter as an exhibit.